2023Shanghai International Biomedical Industry Week
10month16day,2023The opening ceremony of the Shanghai International Biomedical Industry Week (referred to as 'Industry Week') was held at the Zhangjiang Science Hall in Shanghai. This year's Industry Week lasts for five days and is themed 'Working Together for a Shared Future, Full of Vitality'. Adhering to the concept of 'high-end, distinctive, and international', it aims to set industry benchmarks with innovative achievements, lead industry trends with leading enterprises, boost industry enthusiasm through rich activities, and implement the purpose of the event through in-depth exchanges.1The high-specification opening event, nearly40The event consists of high-level concurrent activities and will host a series of Industry Week events throughout the year, forming a “5+360" (i.e., Industry Week5Tianjin Central Activity360The activity pattern of regular activities (daily routine activities).
This year's Industry Week brought together thousands of heavyweight guests from the global biopharmaceutical field. Top experts from academia, including representatives of international organizations such as the International Pharmaceutical Federation(FIP)Chair Paul Sinclair(Paul Sinclair),2022,2001Carl Barrie Sharpless, two-time Nobel laureate in chemistry(K. Barry SHARPLESS)Academicians of the Chinese Academy of Sciences Chen Kaixian and Jin Li, Academicians of the Chinese Academy of Engineering Chen Sajuan and Yang Shengli, Professor Lu Bai from the School of Pharmacy at Tsinghua University, and nearly30Academicians and experts from other fields discussed cutting-edge tracks; over a hundred iconic domestic and international biopharmaceutical entrepreneurs, such as Roche Group Chairman Jean-Pierre Sauvagnat and Moderna CEO Stefan Neuberger · Bäser, discussed international opportunities; representatives of leading investment and financing, ecosystem service providers, such as Frost & Sullivan (Frost & SullivanFrost & Sullivan, abbreviated as 'Frost & Sullivan', E Fund,BCGBoston, McKinsey, JPMorgan Chase, and the world's four leading accounting firms are jointly paying attention to industry hotspots, focusing on global industrial innovation trends, working together to create an open and integrated industrial landscape, and delving into the future of industries with high-quality development.
10month17day,2023The Forum on Supporting the High-quality Development of the Biopharmaceutical Industry with an Innovative Medical Insurance System, one of the concurrent activities of the Shanghai International Biomedical Industry Week, was successfully held at the Shanghai Hengshan North Suburb Hotel. The forum focused on how to further advance the supply-side reform of medical services, encourage biopharmaceutical enterprises to innovate, and promote Shanghai's efforts to build a globally influential innovation hub for the biopharmaceutical industry, aiming to assist in achieving sustainable development of the medical security system.
This forum is guided by the Shanghai Municipal Commission of Economy and Informatization, the Shanghai Municipal Medical Security Bureau, and the People's Government of Baoshan District, Shanghai. It is co-hosted by the Shanghai Biomedical Industry Promotion Center, the Shanghai Medical Centralized Bidding and Procurement Affairs Management Office, the Shanghai Baoshan District Economic Committee, and the Shanghai Baoshan District Medical Security Bureau, and organized by R & D Guest.
Zhang Xiong, Deputy Secretary-General of the Shanghai Municipal People's Government; Xia Kehua, Secretary of the Party Leadership Group and Director of the Shanghai Medical Security Bureau; Wang Nai, Standing Committee Member and Deputy District Mayor of Baoshan District; Xue Sasa, Deputy District Mayor of Baoshan District; Zhang Chao, Member of the Party Leadership Group and Deputy Director of the Shanghai Medical Security Bureau; Yu Baorong, Professor at the School of Insurance of the University of International Business and Economics; Li Xin, Deputy Dean and Professor of Pharmacy at Nanjing Medical University; Hou Lei, Global Managing Partner at McKinsey;RDPACGuests attending the forum included Chief Executive Officer Kang Wei, Secretary-General of the Pharmaceutical Promotion Association Feng Lan, General Manager of Magnesium Health Kangfu Zhiyao He Zhixiang, General Manager of China Life Reinsurance Shanghai Branch Gu Xiu, General Manager of the Life Insurance and Property Insurance Department of China Taiping Life Insurance Yuan Xudong, Director of Health Affairs and Market Access at Boehringer Ingelheim Han Ting, and Head of Health Economics and Real World Research in the Asia-Pacific Region at Aikunwei Xie Yang.
Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, was invited to attend the forum and delivered a speech on 'Analysis of the Current Development Status of Innovative Payments'. He also served as the moderator of the roundtable forum, exploring with the participants how diverse payment mechanisms can drive the innovative development of the biopharmaceutical industry.
Deputy Secretary-General of the Shanghai Municipal People's Government Zhang Xiong
Zhang Xiong, Deputy Secretary-General of the Shanghai Municipal People's Government, delivered a speech at this forum. In his speech, he stated that the development of the biopharmaceutical industry cannot be separated from the full-chain support of innovation chains, industrial chains, talent chains, and capital chains, and even more so from stable market expectations. This year, Shanghai has introduced a number of measures to support innovation in the pharmaceutical industry, especially focusing on empowering the innovative development at the front end of the industry by improving the payment and application mechanisms at the back end of the pharmaceutical industry. For example, further improving the diversified payment mechanism and supporting the development of innovative drugs and medical devices “28The measures involve establishing a diversified payment mechanism for innovative drugs and medical devices through basic medical insurance and commercial health insurance. This promotes the inclusion of more high-quality innovative drugs and medical devices into the payment scope, facilitates the supply-side reform of medical services, enhances the accessibility and affordability of innovative drugs and medical devices, guides the positive development expectations of biopharmaceutical enterprises, and at the same time aids in the development of Shanghai's insurance and finance industry. These practical measures have sent out positive market signals, playing a role in stabilizing expectations and boosting confidence for the development of pharmaceutical enterprises.
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
During the keynote speech session, Mao Hua delivered a presentation focusing on "The Current Development Status of Innovative Payments." He pointed out that there is still significant room for improvement outside basic medical insurance, and innovative payments are integrated into new drugs./The extended lifecycle after device approval for marketing can effectively reduce the economic burden on patients. Looking at the medical insurance markets of developed countries and regions around the world, foreign innovative payment systems are maturely developed. Diverse models such as charitable drug donations, financial payments, and innovative commercial health insurance coexist, effectively meeting the diverse needs of the public.
Mao Hua said that with the deepening of population aging, China's healthcare system is under tremendous pressure, and per capita medical expenditure is still at a relatively low level compared to developed countries. In recent years, basic medical insurance has improved its basic security capabilities through measures such as improving the selection mechanism and refined management.2022The total number of drugs in the medical insurance catalog for the year reached2,967plant111The number of newly added drugs to the catalog saw an average price cut of60%At the same time, it supports innovative access, actively including innovative drugs with high clinical value, significant patient benefits, and excellent economic evaluations in medical insurance negotiations.2022Among the newly added drugs in the annual catalogue,23It was newly listed back then24A major innovative drug from a certain country has been included in negotiations.
"The personal portion of medical expenditures in our country is relatively high, and the potential for commercial insurance compensation expenditures remains untapped. At the same time, our country's commercial medical insurance coverage for pre-existing conditions and patients with chronic illnesses is quite insufficient," Mao Hua further stated. "We can also see that at this stage, our country is actively exploring innovative payment models and accelerating the construction and improvement of an innovative medical security payment system, such asPAPModels, medical stages, people's livelihood insurance, etc. In the future, driven by favorable policies and the joint efforts of biopharmaceutical companies, it is expected to promote industry ecosystem innovation, achieve sustainable development of the medical security system, realize high-quality development of the biopharmaceutical industry, and ultimately benefit more patients.
Subsequently, Mao Hua served as the moderator of the roundtable. He discussed with He Zhixiang, General Manager of Magnesium Health Kangfu Smart Medicine, Gu Xiu, General Manager of China Life Reinsurance Shanghai Branch, Yuan Xudong, General Manager of China Taiping Life Insurance's Life and Property Insurance Department, and Han Ting, Director of Health Affairs and Market Access at Boehringer Ingelheim, focusing on 'Exploring Diverse Payment Mechanisms to Promote Innovative Development in the Biopharmaceutical Industry'. They explored how diverse payment mechanisms can play a role in the biopharmaceutical industry to facilitate innovation and development.
More wonderful moments from forums
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life science industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, accumulating extensive project experience in various subfields of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-fields such as pharmaceuticals and medical devices, attracting wide attention from investors.
